Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSC in ALS
NCT02290886Phase 2Completed
- Start
- Jul 2014
- Primary completion
- Mar 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous adipose-derived mesenchymal stromal cells in amyotrophic lateral sclerosis (ALS). Started Jul 2014; status: completed.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02290886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02290886.